Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

RELATED NEWS
Trade FRX now with 

Forest Laboratories, Inc. (FRX: Quote) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

Click here to receive FREE breaking news email alerts for Forest Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a surprise move, the Senate voted Tuesday to make changes to an important House highway funding bill, raising questions about whether the legislation will receive final approval before lawmakers leave town for the August recess. Stocks have given back some ground over the course of the trading day on Wednesday after failing to sustain an early upward move. The choppy trading reflects uncertainty ahead of a highly anticipated announcement from the Federal Reserve. After reporting a notable contraction in U.S. economic activity in the first quarter, the Commerce Department released a report on Wednesday showing that gross domestic product rebounded by more than anticipated in the second quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.